Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGynecological OncologySarcomasDiseaseEndometrial CancerSubgroupICD10C54.1MeSHCarcinosarcomaSequenceAntineoplastic therapySubstanceCisplatinIfosfamideSubstanceCisplatinIfosfamideSubstanceCisplatinIfosfamideSubstanceCisplatinIfosfamideNo. Substances2 RadiotherapySupportive therapySubstanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSubstanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSubstanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSubstanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfateMesnaPegfilgrastimPotassium chlorideNo. Substances8Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentioncurativeRisksAnemia Hb below 8g/dlCardiotoxicityEmetogenicity (MASCC/ESMO)Gastrointestinal ToxicityInfectionsNeuropathy only studiesPublicationAuthorWolfson AHDiseaseKarzinosarkom des Uterus, FIGO-Stadium I-IVOriginSylvester Cancer Center, University of Miami Miller School of Medicine, Miami, USAProtocols in Revision 1 protocol foundIfosfamide 1.5 / Cisplatin 20, Uterine Carcinosarcoma, adjuvant (PID1584 V1.1)
